News - Novo Nordisk

Filter

Current filters:

Novo Nordisk

Popular Filters

1 to 25 of 135 results

Glowing prospects for Novo Nordisk's insulin degludec/liraglutide for type 2 diabetes

Glowing prospects for Novo Nordisk's insulin degludec/liraglutide for type 2 diabetes

07-07-2014

Danish diabetes care giant Novo Nordisk's fixed-dose combination therapy insulin degludec/liraglutide…

DiabetesEuropeIDegLiraMarkets & MarketingNovo NordiskPharmaceuticalUSAXultophy

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

23-06-2014

New data for Danish diabetes care giant Novo Nordisk’s liraglutide 3mg from the Phase IIIa SCALET Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

Novo Nordisk launch new insulin device Levemir FlexTouch in USA

Novo Nordisk launch new insulin device Levemir FlexTouch in USA

19-06-2014

Danish diabetes care giant Novo Nordisk has launched its newest prefilled insulin delivery device Levemir…

DiabetesLevemirMarkets & MarketingNovo NordiskPharmaceuticalUSA

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

15-06-2014

A new Phase IIIa study shows that IDegLira, the once-daily single injection combination of Danish diabetes…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchVictoza

6,000 new jobs in Novo Nordisk create a further 15,000 jobs in Denmark

6,000 new jobs in Novo Nordisk create a further 15,000 jobs in Denmark

11-06-2014

Up to 2022, Danish diabetes care giant Novo Nordisk expects to hire 6,000 new employees in Denmark, half…

BoardroomDenmarkDiabetesManagementNovo NordiskPharmaceutical

Quebec first province to add Victoza to the drug benefit formulary

Quebec first province to add Victoza to the drug benefit formulary

04-06-2014

The Canadian subsidiary of Danish diabetes care giant Novo Nordisk says that the Quebec government has…

CanadaDiabetesFinancialHealthcareNovo NordiskPharmaceuticalVictoza

Significantly greater weight loss versus placebo seen in Ph IIIa study of liraglutide 3mg

16-05-2014

Significant weight loss was demonstrated for Danish insulin giant Novo Nordisk’s diabetes drug liraglutide…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

Preventative treatment with NovoEight reduces bleeding in hemophilia A

Preventative treatment with NovoEight reduces bleeding in hemophilia A

12-05-2014

Danish insulin giant Novo Nordisk has announced new Phase III interim data from its guardianT2 trial…

Coagulation systemDenmarkGuardianT2HematologyInsulin giantNovo NordiskNovoEightPharmaceuticalResearchVIII (rFVIII)World Congress

Healthy 1st-qtr growth reported Novo Nordisk, which beats forecasts

Healthy 1st-qtr growth reported Novo Nordisk, which beats forecasts

01-05-2014

Danish diabetes care giant Novo Nordisk increased operating profit in local currencies by 15% in the…

DiabetesNovo NordiskPharmaceutical

IQWiG finds added benefit for Novo Nordisk’s NovoEight not proven

23-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyHematologyNorthern EuropeNovo NordiskNovoEightPharmaceuticalPricingRegulation

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

31-03-2014

Marking a second regulatory hurdle for the breakthrough product, the US Food and Drug Administration…

AlprolixBenefixBiogen IdecBiotechnologyCSL LimitedHematologyNorth AmericaNovo NordiskPfizerRegulationSwedish Orphan BiovitrumUSA

Label updates for Tresiba and Victoza backed by EMA committee

21-03-2014

The European Medicines agency’s Committee for Medicinal Products for Human Use has issued positive…

DiabetesEuropeNovo NordiskPharmaceuticalRegulationTresibaVictoza

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

19-03-2014

Danish insulin giant Novo Nordisk says it has completed the pathfinderT2, the first Phase III trial with…

HematologyN8-GPNovo NordiskPharmaceuticalResearchturoctocog alfa

Novo Nordisk invests $100 million in new purification pilot plant in Denmark

Novo Nordisk invests $100 million in new purification pilot plant in Denmark

14-03-2014

Danish insulin giant Novo Nordisk revealed this morning that it is increasing its drug development capacity…

DiabetesFinancialNovo NordiskPharmaceuticalProduction

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11-03-2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

05-03-2014

Danish insulin giant Novo Nordisk has presented positive data at the Diabetes UK conference from its…

DenmarkDiabetesIDegLiraNovo NordiskPharmaceuticalResearchUK

India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector

17-02-2014

The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

Five big pharma firms named as high performers in annual biopharmaceutical report

Five big pharma firms named as high performers in annual biopharmaceutical report

12-02-2014

Entry in emerging markets and expedient product launches are still driving the pharma market, according…

AmgenAstellas PharmaBristol-Myers SquibbFinancialMarkets & MarketingNovo NordiskPharmaceuticalResearchRoche

Novo Nordisk ups stake in Innate Pharma along with sale of anti-NKG2A

Novo Nordisk ups stake in Innate Pharma along with sale of anti-NKG2A

07-02-2014

Danish insulin giant Novo Nordisk has sold full development and commercialization rights to the anti-NKG2A…

anti-NKG2AInnate PharmaLicensingMergers & AcquisitionsNovo NordiskOncologyPharmaceutical

Novo Nordisk’s profits rise 15% with further growth expected

Novo Nordisk’s profits rise 15% with further growth expected

30-01-2014

Danish insulin giant Novo Nordisk has announced a 15% growth in profit in the firm’s 2013 financial…

DenmarkDiabetesFinancialNovo NordiskPharmaceuticalTresibaVictoza

Novo Nordisk launches diabetes collaboration focused on integrated care with London partners

Novo Nordisk launches diabetes collaboration focused on integrated care with London partners

27-01-2014

A unique collaboration between leading London hospitals and Danish insulin giant Novo Nordisk (NOV: N)…

DiabetesHealthcareNovo NordiskPharmaceuticalUK

FDA approves Novo Nordisk’s Tretten to treat rare genetic clotting disorder

FDA approves Novo Nordisk’s Tretten to treat rare genetic clotting disorder

24-12-2013

The US Food and Drug Administration yesterday (December 23) approved Tretten, coagulation factor XIII…

HematologyNorth AmericaNovo NordiskNovoThirteenPharmaceuticalRare diseasesRegulationTretten

Novo Nordisk files for approval of high strength liraglutide for obesity

Novo Nordisk files for approval of high strength liraglutide for obesity

22-12-2013

Danish insulin giant Novo Nordisk has filed separate regulatory submissions with the US Food and Drug…

DiabetesEuropeliraglutideMetabolicsNorth AmericaNovo NordiskPharmaceuticalRegulationVictoza

1 to 25 of 135 results

Back to top